MX9701526A - Terapia combinada para tratar la osteoporosis. - Google Patents
Terapia combinada para tratar la osteoporosis.Info
- Publication number
- MX9701526A MX9701526A MX9701526A MX9701526A MX9701526A MX 9701526 A MX9701526 A MX 9701526A MX 9701526 A MX9701526 A MX 9701526A MX 9701526 A MX9701526 A MX 9701526A MX 9701526 A MX9701526 A MX 9701526A
- Authority
- MX
- Mexico
- Prior art keywords
- bone loss
- parathyroid hormone
- combination therapy
- estrogen agonists
- prevent bone
- Prior art date
Links
- 206010065687 Bone loss Diseases 0.000 title abstract 2
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 2
- 239000000199 parathyroid hormone Substances 0.000 title abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00107—Coatings on the energy applicator
- A61B2018/00148—Coatings on the energy applicator with metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion proporciona nuevos procedimientos de tratar o prevenir la osteoporosis que comprenden administrar a un mamífero que necesite dicho tratamiento una cantidad eficaz de un compuesto de formula I en la que R1 y R2 pueden ser iguales o diferentes, con la condicion de que cuando R1 y R2 son iguales, cada uno es un grupo metilo o etilo y cuando R1 y R2 son diferentes, uno de ellos es un grupo metilo o etilo y el otro es hidrogeno o un grupo bencilo; o una sal farmacéuticamente aceptable del mismo; junto con un polifosfanato inhibidor de la resorcion osea, o hormona paratiroidea.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US012409 | 1987-02-09 | ||
| US1240996P | 1996-02-28 | 1996-02-28 | |
| US1239996P | 1996-02-28 | 1996-02-28 | |
| US012399 | 1996-02-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9701526A true MX9701526A (es) | 1998-06-28 |
| MXPA97001526A MXPA97001526A (es) | 1998-10-30 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| AU1497897A (en) | 1997-09-04 |
| CA2198580C (en) | 2001-07-03 |
| CN1166316A (zh) | 1997-12-03 |
| ZA971711B (en) | 1998-08-27 |
| US5773477A (en) | 1998-06-30 |
| AU718242B2 (en) | 2000-04-13 |
| JPH09328430A (ja) | 1997-12-22 |
| KR970061249A (ko) | 1997-09-12 |
| IL120270A0 (en) | 1997-06-10 |
| EP0792639A1 (en) | 1997-09-03 |
| CA2198580A1 (en) | 1997-08-28 |
| US5861438A (en) | 1999-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL124459A0 (en) | Antagonists of gonadotropin releasing hormone | |
| MX9804850A (es) | Antagonistas de hormona liberadora de gonadotropina. | |
| CA2245142A1 (en) | New phenanthridines | |
| MY119403A (en) | Novel compounds with analgesic effect. | |
| CA2198535A1 (en) | Method of increasing testosterone | |
| BG105568A (en) | Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent | |
| SG127714A1 (en) | Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes | |
| AP2002002458A0 (en) | Compounds for the treatment of ischemia. | |
| PL347671A1 (en) | Compounds and compositions for delivering active agents | |
| MY116478A (en) | Tri-substituted imidazoles having multiple therapeutic properties | |
| DE69311556D1 (de) | Inhalationspulver enthaltend antistatisches hilfsmittel | |
| MX9702380A (es) | Nuevas carboxamidas con actividad antifungica. | |
| UA41355C2 (uk) | Засіб для лікування нейро-сніду | |
| CY2431B1 (en) | Novel phenanthridines substituted in the 6 position. | |
| EP0938317A4 (en) | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | |
| ZA922297B (en) | Crystalline tiababine monohydrate,its preparation and use | |
| CA2198580A1 (en) | Combination therapy to treat osteoporosis | |
| MX9504023A (es) | Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion. | |
| NO984920L (no) | Preparater omfattende en nitronforbindelse for anvendelse ved behandling av okulµr inflammasjon | |
| MX9709466A (es) | Medicamento para inhibir el melanoma. | |
| MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
| MX9701606A (es) | Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno. | |
| BR9915214A (pt) | Combinações contendo um beta-agonista e umagente anti-diabético adicional | |
| AU4944899A (en) | New pharmaceutically active compounds | |
| TW330933B (en) | Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes |